Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.

In a matched real-world cohort, conversion from calcineurin inhibitors to belatacept-based immunosuppression was associated with superior 7-year death-censored allograft survival and acceptable safety, at the cost of more de novo proteinuria.